Investor Relations, Email: ir@nuvoresearch.comCopyright CNW Group 2015
Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial
On 6ix: 6ix.com/news/nuvo-researchandxae-provides-update-on-pennsaidandxae-2percent-phase-3-clinical-trial
View original source (CNW)Nuvo Pharmaceuticals Inc on 6ix
Story so far
Earlier from Nuvo Pharmaceuticals
- Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants
- Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc.
- Nuvo Research® Announces 2015 Third Quarter Results
- Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia
- Nuvo Research® Announces Appointment to its Board of Directors
Later from Nuvo Pharmaceuticals
- Nuvo Research® Announces Special Shareholder Meeting to Vote on Reorganization of Nuvo into Two Publicly Traded Companies
- Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10(TM) for the Treatment of Allergic Rhinitis
- Nuvo Research® Reacquires Pliaglis North American Development and Marketing Rights
- Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End
- Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement
Follow Nuvo Pharmaceuticals into a list and get an email when it puts out news.
Follow Nuvo Pharmaceuticals